

## Hello *JNCCN* Readers

It is with great excitement that I say hello to all of you, our readers, and begin my tenure as the Editor-in-Chief of *JNCCN*—*Journal of the National Comprehensive Cancer Network*.


First, I want to thank Dr. Margaret Tempero for her incredible leadership over the past 10 years, as she helped to steward *JNCCN* from an impact factor of 4 to 13, increase its visibility and submissions, and assemble a diverse and incredibly knowledgeable editorial board. She leaves *JNCCN* stronger than ever, and I am humbled to pick up the baton.

I also want to express my gratitude to the NCCN leadership and management team for the opportunity to take on this critical role. NCCN is a foundational organization in oncology. In serving our community of providers, patients, and caregivers via the delivery of the highest quality guidelines, educational programs, patient resources, and research opportunities, the organization is helping to improve the care of patients worldwide (the top priority of any clinician), and to educate the next generation of oncologists. I have had the privilege of being part of the NCCN Guidelines Panel for Testicular Cancer and know firsthand the type of expertise and deep thought that drives NCCN recommendations; helping to advance and disseminate those advances via *JNCCN* is exciting!

Furthering NCCN's mission to "improve and facilitate quality, effective, equitable, and accessible cancer care" will remain a key cornerstone of the journal. My goals for *JNCCN* are perhaps obvious—to continue to increase the journal's stature, readership, and visibility in the oncology community, while maintaining its core strengths of quality and scientific rigor. I will do this by partnering with the editorial board and editorial staff to consider new initiatives that can further help our readers and the oncology community. This may be starting a new section such as "Beyond the Guidelines," in which a case vignette catapults the discussion of expert treatment of a particular disease scenario or clinical dilemma; widening the scope of the journal to include more clinical trials and research results that have evolved from the NCCN's Oncology Research Program (ORP); and engaging with our readers to increase our online presence. At the same time, as Dr. Tempero wrote in 2014 when she began in this role, "*JNCCN* will still broadcast changes in the NCCN Guidelines and feature articles that naturally spring from the guidelines process."<sup>1</sup> Finally, we want to involve and encourage submissions from a worldwide community of investigators and bring in fresh voices.

Importantly, if you have ideas, thoughts, criticisms, or suggestions of how to make *JNCCN* better or more applicable for your practice, or what you would like to see more or less of, please reach out.

We are fortunate to live in an era of rapid change and breakthroughs in oncology, and I hope that we can keep or make *JNCCN* a monthly destination for you to follow this progress.



### DANIEL M. GEYNISMAN, MD

Daniel M. Geynisman, MD, is an Associate Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center and the Division Chief of Genitourinary Medical Oncology, as well as the Vice Chair for Quality Improvement. He is also the Editor-in-Chief of *JNCCN* as of May 2024.

Dr. Geynisman clinically sees patients with all urologic malignancies—bladder, kidney, prostate, penile, testicular, and adrenal cancers. His research interests focus on health outcomes evaluations in urologic malignancies, quality improvement in oncology, and new drug development for genitourinary malignancies. He is an active investigator on a number of past and ongoing clinical trials, with a particular focus in bladder and kidney cancer, and he has co-authored more than 130 manuscripts in peer-reviewed journals.

He serves on the NCCN Guidelines Panel for Testicular Cancer, is on ASCO's Ethics Committee, and is the prior medical oncology editor for *Urologic Oncology*.

Dr. Geynisman earned his medical degree from the University of Pittsburgh School of Medicine and completed a residency in internal medicine at the University of Pittsburgh Medical Center, serving an additional year as chief resident. He then went on to a fellowship in hematology/oncology at the University of Chicago, serving as a chief fellow in his final year of training.

*J Natl Compr Canc Netw* 2024;22(2D):e240031

doi:10.6004/jnccn.2024.0031

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

### Reference

1. Tempero M. *JNCCN* going forward. *J Natl Compr Canc Netw* 2014;12:301.



**WHAT DO YOU THINK?** To submit a Letter to the Editor, email [JNCCN@nccn.org](mailto:JNCCN@nccn.org) or log into [www.editorialmanager.com/JNCCN](http://www.editorialmanager.com/JNCCN).